Addex Therapeutics Ltd (ADXN)
Addex Therapeutics Ltd operates in the Biotechnology industry of the Healthcare sector, headquartered in Geneva, GE, CH. The stock last traded at $5.38, down 9.58% on the session, giving a market capitalisation of $6.6M. On trailing twelve-month figures it carries a trailing P/E of -0.73, a net margin of -7775.2%. Its beta of 2.00 implies it has historically moved more than the broad market.
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Addex Therapeutics Ltd is most often compared with the following Healthcare names: